Bifogade filer
Kurs & Likviditet
Kalender
2025-02-11 | Bokslutskommuniké 2024 |
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-08-06 | Kvartalsrapport 2024-Q2 |
2024-05-22 | Ordinarie utdelning RESP 0.00 SEK |
2024-05-21 | Årsstämma 2024 |
2024-05-21 | Kvartalsrapport 2024-Q1 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-11-14 | Kvartalsrapport 2023-Q3 |
2023-08-08 | Kvartalsrapport 2023-Q2 |
2023-05-17 | Ordinarie utdelning RESP 0.00 SEK |
2023-05-16 | Kvartalsrapport 2023-Q1 |
2023-05-16 | Årsstämma 2023 |
2023-02-07 | Bokslutskommuniké 2022 |
2022-11-08 | Kvartalsrapport 2022-Q2 |
2022-08-30 | Kvartalsrapport 2022-Q1 |
2022-06-10 | Ordinarie utdelning RESP 0.00 SEK |
2022-06-09 | Årsstämma 2022 |
2022-05-13 | Bokslutskommuniké 2021 |
2022-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2022-03-14 | Extra Bolagsstämma 2022 |
2021-11-10 | Kvartalsrapport 2021-Q3 |
2021-08-06 | Kvartalsrapport 2021-Q2 |
2021-06-10 | Årsstämma 2021 |
2021-05-28 | Ordinarie utdelning RESP 0.00 SEK |
2021-05-27 | Kvartalsrapport 2021-Q1 |
2021-02-03 | Bokslutskommuniké 2020 |
2020-11-04 | Kvartalsrapport 2020-Q3 |
2020-08-25 | Kvartalsrapport 2020-Q2 |
2020-05-20 | Ordinarie utdelning RESP 0.00 SEK |
2020-05-19 | Årsstämma 2020 |
2020-05-19 | Kvartalsrapport 2020-Q1 |
2020-02-04 | Bokslutskommuniké 2019 |
2019-11-07 | Kvartalsrapport 2019-Q3 |
2019-08-30 | Kvartalsrapport 2019-Q2 |
2019-05-29 | Ordinarie utdelning RESP 0.00 SEK |
2019-05-28 | Kvartalsrapport 2019-Q1 |
2019-05-28 | Årsstämma 2019 |
2019-02-05 | Bokslutskommuniké 2018 |
2018-11-07 | Kvartalsrapport 2018-Q3 |
2018-08-28 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Ordinarie utdelning RESP 0.00 SEK |
2018-05-15 | Kvartalsrapport 2018-Q1 |
2018-05-15 | Årsstämma 2018 |
2018-02-06 | Bokslutskommuniké 2017 |
2017-11-07 | Kvartalsrapport 2017-Q3 |
2017-08-29 | Kvartalsrapport 2017-Q2 |
2017-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2017-05-02 | Årsstämma 2017 |
2017-05-02 | Kvartalsrapport 2017-Q1 |
2017-02-08 | Bokslutskommuniké 2016 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-01 | Kvartalsrapport 2016-Q2 |
2016-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2016-05-02 | Årsstämma 2016 |
2016-05-02 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-11-04 | Kvartalsrapport 2015-Q3 |
2015-08-06 | Kvartalsrapport 2015-Q2 |
2015-04-30 | Ordinarie utdelning RESP 0.00 SEK |
2015-04-29 | Kvartalsrapport 2015-Q1 |
2015-04-29 | Årsstämma 2015 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-10-30 | Kvartalsrapport 2014-Q3 |
2014-07-30 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Ordinarie utdelning RESP 0.00 SEK |
2014-05-05 | Årsstämma 2014 |
2014-05-05 | Kvartalsrapport 2014-Q1 |
2014-02-28 | Bokslutskommuniké 2013 |
2013-11-07 | Kvartalsrapport 2013-Q3 |
2013-08-21 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Ordinarie utdelning RESP 0.00 SEK |
2013-05-20 | Kvartalsrapport 2013-Q1 |
2013-05-20 | Årsstämma 2013 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-11-30 | Kvartalsrapport 2012-Q3 |
2012-08-31 | Kvartalsrapport 2012-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Respiratorius announces that the last subjects in the ongoing PK study of VAL001 has been dosed.
The tailored release profile of VAL001, combining immediate release and extended-release characteristics of sodium valproate, is evaluated in the pharmacokinetic (PK) study in healthy subjects. Preliminary results of the initial part of the study were evaluated during March 2022.
"We are very pleased with the recruitment and that we have been able to keep to the timelines while still some pandemic related restrictions being effective. Now a short follow-up period is remaining followed by analysis of the results and a formal closure of the study," says CEO Johan Drott in a comment.
This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-06-2022 10:59 CET.
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com